Organized Approaches to Increase Colorectal Cancer Screening ***AMENDMENT TO FAQs- Changes to Question and Answer 14***
Funding Opportunity Number: CDC-RFA-DP15-1502 Opportunity Category: DiscretionaryFunding Instrument Type: Cooperative AgreementCategory of Funding Activity: HealthCFDA Number: 93.800Eligible Applicants State governmentsPublic and State controlled institutions of higher educationNative American tribal governments (Federally recognized)Private institutions of higher educationAgency Name: HHS-CDCClosing Date: Apr 14, 2015Award Ceiling: $1,800,000Expected Number of Awards: 35Creation Date: Mar 25, 2015Funding Opportunity Description: The purpose of the program is to increase CRC screening rates among an applicant-defined target population of persons 50-75 years of age within partner health system(s), defined geographical areas, or disparate populations. This program will fund implementation of EBIs and other strategies in partnership with health systems with the goal of instituting organized screening programs. In addition, this program will fund a small number of awardees to pay for direct screening and follow-up services for a limited number of individuals that belong to the Program Priority Population. The Program Priority Population to receive CRC services is defined as: persons ages 50-64 who are asymptomatic and at average risk for CRC, with inadequate or no health insurance for CRC screening, and with income at or below 250% of the Federal Poverty Guidelines (FPG). Component 1: Health Systems Change to Increase and Improve Colorectal Cancer (CRC) Screenin...
CONCLUSIONS: outpatient study did not reduce the quality of care and did not delay treatment. PMID: 31729234 [PubMed - as supplied by publisher]
We describe the principal mechanisms of resistance to anti-VEGF therapy and discuss potential biomarkers to be investigated in the near future.
Publication date: Available online 16 November 2019Source: Cancer EpidemiologyAuthor(s): Donata Linkeviciute-Ulinskiene, Audrius Dulskas, Ausvydas Patasius, Lina Zabuliene, Vincas Urbonas, Giedre Smailyte
CONCLUSIONS: Considering the age group in which rectal prolapse is most commonly seen, and the change in bowel habits, chronic constipation and irritation chronic seen in rectal prolapse may be responsible for the development of rectum cancer, therefore endoscopic screening should not be overlooked in rectal prolapse cases. KEY WORDS: Anorectal emergencies, Colon cancer, Rectal prolapse. PMID: 31723051 [PubMed - in process]
Authors: Grothey A, Marshall JL, Bekaii-Saab T PMID: 31730592 [PubMed - in process]
Authors: Grothey A PMID: 31730591 [PubMed - in process]
Authors: Bekaii-Saab T PMID: 31730590 [PubMed - in process]
Authors: Marshall JL PMID: 31730589 [PubMed - in process]
Authors: Grothey A, Marshall JL, Bekaii-Saab T Abstract The standard treatment for patients with metastatic colorectal cancer (mCRC) in the first- and second-line setting is generally chemotherapy, which can be augmented with vascular endothelial growth factor-targeted therapies and, for patients with KRAS wild-type status, epidermal growth factor receptor-targeted therapies. However, nearly all patients ultimately develop disease progression and require later lines of therapy. Traditionally, physicians recycled chemotherapy in the later lines, with many patients showing diminished or no response. However, the past...
Publication date: Available online 16 November 2019Source: Journal of Advanced ResearchAuthor(s): Chi-Cheng Huang, Ming-Hung Shen, Shao-Kuan Chen, Shung-Haur Yang, Chih-Yi Liu, Jiun-Wen Guo, Kang-Wei Chang, Chi-Jung HuangAbstractTumor metastasis or recurrence often occurs in patients with curative resection of colorectal cancer (CRC). Placental-specific 8 (PLAC8), which has increased expression in stool, may be associated with CRC recurrence. Insights into the role of PLAC8 in CRC recurrence and its clinical significance may support to develop strategies for preventing CRC recurrence and deterioration. Clinical tissues, ce...